2024 EBMT Meeting Reporter

home / publications / supplements / 2024-ebmt-meeting-reporter
Amandeep Salhotra, MD, of City of Hope

Orca-T Offers Favorable Post-Transplant Outcomes in Advanced Hematologic Malignancies

Courtney Flaherty
May 7th 2024
Article

Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Ashling Wahner
April 17th 2024
Article

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Richard Maziarz, MD, medical director, Blood & Marrow Transplant & Cellular Therapy Program, Oregon Health and Science University

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Courtney Flaherty
April 16th 2024
Article

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.

Jack Gallagher, anesthetics trainee, simulation fellow, St George’s University Hospitals NHS Foundation Trust

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

Ashling Wahner
April 15th 2024
Article

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Amandeep Salhotra, MD, of City of Hope

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

Megan Hollasch
April 15th 2024
Article

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Alejandro Villar-Prados, MD, PhD, of Stanford University School of Medicine

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

Kyle Doherty
April 15th 2024
Article

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.